At a Glance
Breega has established itself as a prominent European early-stage venture capital firm since its founding in 2015, managing approximately $400 million in assets under management across multiple funds. The Paris-based firm has built a reputation for backing enterprise software, marketplace, and digital health companies across Western Europe, with a particular strength in identifying B2B SaaS opportunities before they scale internationally. The firm's investment approach centers on partnering with European entrepreneurs who are building category-defining companies, typically writing initial checks between €500,000 and €5 million at seed and Series A stages. Breega has demonstrated consistent ability to spot early-stage winners, with notable portfolio companies including accounting software provider Pennylane, which raised significant Series A funding, and various marketplace businesses that have achieved meaningful scale across European markets. The firm's geographic focus on Western Europe, particularly France, Germany, and the UK, has positioned it well during a period of substantial growth in the European startup ecosystem. Unlike many traditional European VCs that historically focused on later-stage opportunities, Breega positioned itself from inception as a true early-stage specialist, competing directly with top-tier seed funds while maintaining operational expertise in scaling European companies for international expansion. The firm's relatively compact fund size allows for concentrated bets on high-conviction opportunities while maintaining meaningful ownership stakes. Breega's investment committee includes partners with operational backgrounds in scaling technology companies, providing portfolio companies with practical guidance on market expansion, product development, and fundraising strategy. The firm has consistently deployed capital at a steady pace, typically making 15-20 investments per fund cycle, with reserve capacity for follow-on investments in breakout companies. Their digital health investments have gained particular attention as European healthcare technology has matured, positioning the firm at the intersection of regulatory complexity and technological innovation.
“Focuses on early-stage European B2B SaaS, marketplaces, and digital health companies with global potential.”
Breega's partnership includes experienced investors and operators with deep European market knowledge and scaling expertise. The firm's investment team combines traditional venture capital experience with operational backgrounds in building and scaling technology companies across European markets. Partners bring experience from both entrepreneurial ventures and established technology companies, providing portfolio companies with practical guidance on market entry strategies, regulatory navigation, and international expansion. The team's collective expertise spans enterprise software sales, marketplace dynamics, and healthcare technology regulations, directly aligning with their core investment sectors.
Breega has raised multiple funds since 2015, progressively increasing fund sizes as the firm established its track record in European early-stage investing. The firm's fund progression reflects the maturation of the European venture capital market, with each successive fund allowing for larger initial investments and increased reserve ratios for follow-on funding. Their fund deployment strategy has remained consistent across fund cycles, maintaining focus on seed and Series A opportunities while expanding geographic reach within Western Europe.
Breega primarily invests at the Seed, Series A stages. This means they focus on companies that are building their initial product and finding product-market fit.
Breega is headquartered in Paris, France. Many of their portfolio companies are also based in this region, though they invest across geographies.
Breega focuses on investments in SaaS, Marketplace, Digital Health. Their portfolio reflects deep expertise and networks within these sectors.
Breega manages approximately $400M in assets under management (AUM) across their funds.
